Oncternal Therapeutics Inc (NAS:ONCT)
$ 8.179 -0.456 (-5.28%) Market Cap: 24.21 Mil Enterprise Value: -9.73 Mil PE Ratio: 0 PB Ratio: 0.80 GF Score: 50/100

Oncternal Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 08:30PM GMT
Release Date Price: $6.18 (+1.75%)
Unidentified Analyst

Good afternoon, everyone. We'll get started now. Welcome to the Jefferies 2023 Global Healthcare Conference. It's my pleasure to introduce James Breitmeyer, the President and CEO of Oncternal Therapeutics. turn it over to you, James.

James Breitmeyer
Oncternal Therapeutics, Inc. - President & CEO

Thank you, and thank you for your time and attention this afternoon. These are our forward-looking statements. Oncternal Therapeutics is a San Diego-based company that is developing products for patients with high unmet medical need, in particular, in hematology and in the area of prostate cancer.

I'm pleased to start my presentation today with the announcement that we opened and treated our first patient yesterday with an autologous ROR1 targeted CAR T therapy called ONCT-808. Right behind that, we have a novel small molecule for the treatment of men with prostate cancer that is resistant to current generation androgen receptor signaling inhibitors. And we also have a ROR1 targeted monoclonal antibody in development that we recently put on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot